ישראל - עברית - Ministry of Health

taro pharmaceutical industries ltd - warfarin sodium - טבליה - warfarin sodium 10 mg - warfarin - warfarin - coumadin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonary embolism. coumadin is indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement. coumadin is indicated to reduce the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction.

ישראל - עברית - Ministry of Health

medison pharma ltd - edoxaban as tosylate - טבליות מצופות פילם - edoxaban as tosylate 15 mg - edoxaban

ישראל - עברית - Ministry of Health

medison pharma ltd - edoxaban as tosylate - טבליות מצופות פילם - edoxaban as tosylate 30 mg - edoxaban

ישראל - עברית - Ministry of Health

medison pharma ltd - edoxaban as tosylate - טבליות מצופות פילם - edoxaban as tosylate 60 mg - edoxaban

ישראל - עברית - Ministry of Health

rafa laboratories ltd - anagrelide as hydrochloride - קפסולות - anagrelide as hydrochloride 0.5 mg - anagrelide - anagrelide - treatment for essential thrombocythemia to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms.

ישראל - עברית - Ministry of Health

sanofi israel ltd - clopidogrel as hydrogen sulfate - טבליות מצופות פילם - clopidogrel as hydrogen sulfate 75 mg - clopidogrel - clopidogrel - prevention of atherotrobmotic eventsclopidogrel is indicated in :• adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.• adult patients suffering from acute coronary syndrome- non-st segment elevation acute coronary syndrome (unstable angina/non-q-wave myocardial infarction (mi)), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapyprevention of atherotrobmotic and thromboembolic events in atrial fibrillation: in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for the treatment with vitamin k antagonists (vka) anti-thrombin or anti factor xa, and who have a low bleeding risk, clopid

ישראל - עברית - Ministry of Health

trima israel pharmaceutical products maabarot ltd - prasugrel - טבליות מצופות פילם - prasugrel 10 mg - prasugrel

ישראל - עברית - Ministry of Health

astrazeneca (israel) ltd - ticagrelor - טבליות מצופות פילם - ticagrelor 60 mg - ticagrelor

ישראל - עברית - Ministry of Health

abic marketing ltd, israel - prasugrel as hydrobromide - טבליות מצופות פילם - prasugrel as hydrobromide 10 mg - prasugrel

ישראל - עברית - Ministry of Health

abic marketing ltd, israel - prasugrel as hydrobromide - טבליות מצופות פילם - prasugrel as hydrobromide 5 mg - prasugrel